title: Efficiency of biological therapies in patients with moderate to severe psoriasis: impact of a pharmacotherapeutic protocol.
abstract: BACKGROUND
  It is not clear how to best use biologics in the treatment of psoriasis. Our objective was to assess use of a protocol for biological therapies (BT) in psoriasis.
  
  
  METHODS
  A consensus protocol was established that included the indications for BT and dose optimization. Patient's characteristics, effectiveness, and cost of BT were analyzed before and after the implementation with two cross-sectional studies to assess its impact.
  
  
  RESULTS
  About 106 were treated before the protocol and 118 patients were treated after. After implementing the protocol, the dose was reduced in 43.4% of the patients receiving adalimumab, in 37.5% for etanercept, in 28.6% for infliximab, and in 14.7% for ustekinumab. No statistically significant differences were found in PASI score after the implementation of the protocol, except for the percentage of patients that achieved PASI 75 with ustekinumab, which was slightly higher. The global yearly savings achieved with the protocol implementation were 115,969 €.
  
  
  CONCLUSIONS
  The protocol helped to increase the efficiency of BT, with decreasing doses of BT without affecting treatment effectiveness.
authors.affiliation: a Department of Pharmacy and.
authors.forename: Rosa Maria
authors.initials: RM
authors.lastname: Romero-Jimenez
authors.affiliation: a Department of Pharmacy and.
authors.forename: Vicente
authors.initials: V
authors.lastname: Escudero-Vilaplana
authors.affiliation: b Department of Dermatology , Hospital General Universitario Gregorio Marañón , Madrid , Spain.
authors.forename: Ofelia
authors.initials: O
authors.lastname: Baniandres Rodriguez
authors.affiliation: a Department of Pharmacy and.
authors.forename: Xandra
authors.initials: X
authors.lastname: Garcia-Gonzalez
authors.affiliation: a Department of Pharmacy and.
authors.forename: Maria
authors.initials: M
authors.lastname: Sanjurjo Saez
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage / Q000191:economics; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001691:Biological Therapy / Q000191:economics / Q000379:methods*; D002985:Clinical Protocols; D032921:Consensus; D017281:Cost of Illness; D003430:Cross-Sectional Studies; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000191:economics; D000068800:Etanercept / Q000008:administration & dosage / Q000191:economics; D005260:Female; D006801:Humans; D000069285:Infliximab / Q000008:administration & dosage / Q000191:economics; D008297:Male; D011565:Psoriasis / Q000628:therapy; D016896:Treatment Outcome; D000069549:Ustekinumab / Q000008:administration & dosage / Q000191:economics
chemical_list: D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept
keywords: Biological therapy; efficiency; pharmacotherapeutic protocol; psoriasis